Nang Kuang and Molteni Enter into an Exclusive Agreement to Commercialize Pain Management Product in Chinese Mainland
Nang Kuang and Molteni Farmaceutici (Molteni) have signed an exclusive agreement in August 2020 for the commercialization of pain management therapy in Mainland China for post-operative care of cancer patients.
Molteni is a leading pharmaceutical company in Europe founded in 1892. It is a specialty leader in the opioid drug market researching and developing solutions for the treatment of pain and addiction.